As of 2025-05-24, the Relative Valuation of Ligand Pharmaceuticals Inc (LGND) is (62.84) USD. This relative valuation is based on P/E multiples. With the latest stock price at 101.60 USD, the upside of Ligand Pharmaceuticals Inc based on Relative Valuation is -161.8%.
The range of the Relative Valuation is (111.44) - 9.46 USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.2x - 22.5x | 19.4x |
| Forward P/E multiples | 38.8x - 67.8x | 53.3x |
| Fair Price | (111.44) - 9.46 | (62.84) |
| Upside | -209.7% - -90.7% | -161.8% |
| Date | P/E |
| 2025-05-23 | -14.77 |
| 2025-05-22 | -14.73 |
| 2025-05-21 | -14.89 |
| 2025-05-20 | -15.25 |
| 2025-05-19 | -15.31 |
| 2025-05-16 | -15.20 |
| 2025-05-15 | -15.04 |
| 2025-05-14 | -15.28 |
| 2025-05-13 | -15.36 |
| 2025-05-12 | -15.47 |
| 2025-05-09 | -15.19 |
| 2025-05-08 | -14.90 |
| 2025-05-07 | -15.35 |
| 2025-05-06 | -15.02 |
| 2025-05-05 | -15.46 |
| 2025-05-02 | -15.90 |
| 2025-05-01 | -15.87 |
| 2025-04-30 | -15.97 |
| 2025-04-29 | -16.19 |
| 2025-04-28 | -15.83 |
| 2025-04-25 | -15.71 |
| 2025-04-24 | -15.78 |
| 2025-04-23 | -15.37 |
| 2025-04-22 | -15.48 |
| 2025-04-21 | -15.24 |
| 2025-04-17 | -15.26 |
| 2025-04-16 | -15.21 |
| 2025-04-15 | -15.53 |
| 2025-04-14 | -15.50 |
| 2025-04-11 | -15.16 |
| 2025-04-10 | -14.73 |
| 2025-04-09 | -15.10 |
| 2025-04-08 | -14.05 |
| 2025-04-07 | -14.45 |
| 2025-04-04 | -14.48 |
| 2025-04-03 | -14.99 |
| 2025-04-02 | -15.81 |
| 2025-04-01 | -15.24 |
| 2025-03-31 | -15.28 |
| 2025-03-28 | -15.65 |
| 2025-03-27 | -15.95 |
| 2025-03-26 | -15.71 |
| 2025-03-25 | -15.95 |
| 2025-03-24 | -16.23 |
| 2025-03-21 | -15.72 |
| 2025-03-20 | -15.91 |
| 2025-03-19 | -15.70 |
| 2025-03-18 | -15.44 |
| 2025-03-17 | -15.98 |
| 2025-03-14 | -15.44 |